Stockscreener 앱 받기
12.35
7.39%
0.85
시장 영업 전:
12.31
-0.04
-0.32%
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Earnings To Watch: Tango Therapeutics Inc (TNGX) Reports Q4 2025 Result - GuruFocus
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - The Motley Fool
TD Cowen Health Care Conference - marketscreener.com
Examining the Future: Tango Therapeutics's Earnings Outlook - Benzinga
TNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Tango Therapeutics Stock Hits Day Low of $10.90 Amid Price Pressure - Markets Mojo
Barclays Global Healthcare Conference - marketscreener.com
Leerink Partners Global Healthcare Conference - marketscreener.com
Insider Sell Alert: Adam Crystal Sells Shares of Tango Therapeutics Inc (TNGX) - GuruFocus
Adam Crystal Sells 54,345 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Officer Sells Shares - TradingView
Tango Therapeutics (TNGX) R&D president sells 54,345 company shares - Stock Titan
Investment Review: Can Tango Therapeutics Inc be recession proofMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Stifel reiterates Tango Therapeutics stock rating at Buy - Investing.com Australia
Stifel reiterates Tango Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4%Here's What Happened - MarketBeat
Adam Crystal sells 18,452 shares; Form 144 lists 54,345 RSUs (TNGX) - Stock Titan
Tango Therapeutics (TNGX) Price Target Increased by 11.32% to 15.19 - Nasdaq
Tango Therapeutics Hits New 52-Week High of $13.60, Up 77.79% - Markets Mojo
Tango Therapeutics Achieves 423.87% Return, Emerges as a Multibagger Stock in Biotechnology Sector - Markets Mojo
Investment Report: Is Tango Therapeutics Inc in a long term uptrendJuly 2025 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year HighHere's Why - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Now Covered by Mizuho - Defense World
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8%Should You Buy? - MarketBeat
Mizuho Initiates Coverage of Tango Therapeutics (TNGX) with Outperform Recommendation - Nasdaq
TNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tango Therapeutics stock hits 52-week high at 13.5 USD - Investing.com
Tango Therapeutics stock hits 52-week high at 13.5 USD By Investing.com - Investing.com UK
Tango Therapeutics (NASDAQ:TNGX) Coverage Initiated at Mizuho - MarketBeat
Mizuho Initiates Tango Therapeutics at Outperform With $19 Price Target - marketscreener.com
Mizuho initiates Tango Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Mizuho initiates Tango Therapeutics stock with outperform rating - Investing.com
Risk Hedge: Is Columbus Acquisition Corp being accumulated by smart moneyWeekly Earnings Recap & High Win Rate Trade Tips - baoquankhu1.vn
FOMO Trade: How does Tango Therapeutics Inc correlate with NasdaqMarket Performance Summary & Consistent Profit Alerts - baoquankhu1.vn
Tango Therapeutics (TNGX) to Release Earnings on Thursday - MarketBeat
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences - Bitget
Tango Therapeutics to Report Fourth Quarter 2025 Financial - GlobeNewswire
Readystate Asset Management LP Trims Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX) - simplywall.st
Is Tango Therapeutics Inc. stock a smart retirement pickWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - mfd.ru
Is Tango Therapeutics Inc. a strong candidate for buy and holdTrade Signal Summary & Stock Market Timing Techniques - mfd.ru
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat - MarketBeat
Insiders At Tango Therapeutics Sold US$727k In Stock, Alluding To Potential Weakness - 富途牛牛
TNGX PE Ratio & Valuation, Is TNGX Overvalued - Intellectia AI
Tango Therapeutics stock hits 52-week high at $13.47 By Investing.com - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week HighShould You Buy? - MarketBeat
Tango Therapeutics stock hits 52-week high at $13.47 - Investing.com
Can Tango Therapeutics Inc. be recession proofJuly 2025 Intraday Action & Weekly Setup with ROI Potential - mfd.ru
TNGX: Pivotal and combination trial data for vopimetostat, plus pipeline updates, are expected this year - TradingView
TNGX: Major clinical milestones for vopimetostat and pipeline updates are expected this year - TradingView
Published on: 2026-02-12 23:58:23 - baoquankhu1.vn
Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $14.80 - Defense World
[SCHEDULE 13G] Tango Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Third Rock sells Tango shares, cutting stake to 4.74% (TNGX) - Stock Titan
0.11%
6.00%
자본화:
|
볼륨(24시간):